DK1036179T3 - Fremgangsmåde til fremstilling af polypeptider med egnet glucosilering - Google Patents

Fremgangsmåde til fremstilling af polypeptider med egnet glucosilering

Info

Publication number
DK1036179T3
DK1036179T3 DK98965223T DK98965223T DK1036179T3 DK 1036179 T3 DK1036179 T3 DK 1036179T3 DK 98965223 T DK98965223 T DK 98965223T DK 98965223 T DK98965223 T DK 98965223T DK 1036179 T3 DK1036179 T3 DK 1036179T3
Authority
DK
Denmark
Prior art keywords
glucosylation
polypeptides
preparation
suitable glucosylation
Prior art date
Application number
DK98965223T
Other languages
English (en)
Other versions
DK1036179T4 (da
Inventor
Reinhard Franze
Horst Eberhardt
Claus Wallerius
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26042141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1036179(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1997153681 external-priority patent/DE19753681A1/de
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Application granted granted Critical
Publication of DK1036179T3 publication Critical patent/DK1036179T3/da
Publication of DK1036179T4 publication Critical patent/DK1036179T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK98965223.5T 1997-12-03 1998-12-02 Fremgangsmåde til fremstilling af polypeptider med egnet glycosilering DK1036179T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1997153681 DE19753681A1 (de) 1997-12-03 1997-12-03 Erythropoietin mit hoher spezifischer Aktivität
EP98113409 1998-07-17
PCT/EP1998/007819 WO1999028455A1 (de) 1997-12-03 1998-12-02 Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung

Publications (2)

Publication Number Publication Date
DK1036179T3 true DK1036179T3 (da) 2006-03-06
DK1036179T4 DK1036179T4 (da) 2014-03-31

Family

ID=26042141

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98965223.5T DK1036179T4 (da) 1997-12-03 1998-12-02 Fremgangsmåde til fremstilling af polypeptider med egnet glycosilering

Country Status (10)

Country Link
US (1) US6673575B1 (da)
EP (1) EP1036179B2 (da)
JP (2) JP3394240B2 (da)
AR (2) AR018023A1 (da)
AT (1) ATE309350T1 (da)
AU (1) AU2051899A (da)
DE (1) DE59813187D1 (da)
DK (1) DK1036179T4 (da)
ES (1) ES2252876T5 (da)
WO (1) WO1999028455A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
WO2002002793A1 (fr) * 2000-07-05 2002-01-10 Japan As Represented By Secretary Of Osaka University Processus de production de glycoproteine
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
AU2002256005A1 (en) * 2001-03-27 2002-10-08 Smithkline Beecham Corporation Control of glycoforms in igg
AU2003249055B2 (en) * 2002-07-15 2008-06-26 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
MXPA05006522A (es) † 2002-12-23 2006-02-17 Bristol Myers Squibb Co Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
DE102004007658B4 (de) * 2004-02-17 2008-12-18 Bioceuticals Arzneimittel Ag Verfahren zur Herstellung von rekombinanten Proteinen in eukaryontischen Wirtszellen
EP1605057A3 (de) * 2004-06-09 2006-11-02 Klaus Heyne Verfahren zur Herstellung hyperglykosylierter Proteine
AR053416A1 (es) * 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
KR101398713B1 (ko) 2005-12-20 2014-06-12 브리스톨-마이어스 스큅 컴퍼니 조성물 및 조성물의 제조 방법
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
DE102008002210A1 (de) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur fermentativen Herstellung von Erythropoietin
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血液凝固タンパク質複合体
JP5918697B2 (ja) 2010-10-15 2016-05-18 Ｊｃｒファーマ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
CA2822591C (en) 2010-12-22 2020-12-29 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
TWI832345B (zh) * 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) * 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
RU2016152693A (ru) * 2014-06-03 2018-07-09 Люпин Лимитед Способ культивирования клеток для получения белка

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935350A (en) * 1985-11-18 1990-06-19 Amgen Materials and methods for controlling plasmid copy number and stability
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
JP3375140B2 (ja) 1991-03-08 2003-02-10 森永製菓株式会社 モノクローナル抗体生産用培地の作製法及びそのキット
ES2164050T3 (es) 1991-04-18 2002-02-16 Toray Industries Preparacion de compuestos de interleuquina-6.
JPH06292592A (ja) * 1993-02-09 1994-10-21 Snow Brand Milk Prod Co Ltd 糖蛋白質の生産方法
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process

Also Published As

Publication number Publication date
AR018023A1 (es) 2001-10-31
EP1036179A1 (de) 2000-09-20
AR020735A1 (es) 2002-05-29
EP1036179B2 (de) 2014-01-01
JP2001525342A (ja) 2001-12-11
US6673575B1 (en) 2004-01-06
ES2252876T3 (es) 2006-05-16
JP2003180392A (ja) 2003-07-02
ES2252876T5 (es) 2014-04-03
AU2051899A (en) 1999-06-16
JP3394240B2 (ja) 2003-04-07
DK1036179T4 (da) 2014-03-31
DE59813187D1 (de) 2005-12-15
WO1999028455A1 (de) 1999-06-10
JP4384400B2 (ja) 2009-12-16
ATE309350T1 (de) 2005-11-15
EP1036179B1 (de) 2005-11-09

Similar Documents

Publication Publication Date Title
DK1036179T3 (da) Fremgangsmåde til fremstilling af polypeptider med egnet glucosilering
DK1038008T3 (da) Fremgangsmåde til fremstilling af EGIII-lignende enzymer
DK0708114T3 (da) Fremgangsmåde til fremstilling af alkylerede galactomannaner
DK1032566T5 (da) Fremgangsmåde til fremstilling af citalopram
DK0812357T3 (da) Fremgangsmåde til fremstilling af heteromultimere polypeptider
DK1005517T3 (da) Fremgangsmåde til fremstilling af diglycerider
DK0790226T3 (da) Fremgangsmåde til fremstilling af methanol
DK0916675T3 (da) Fremgangsmåde til fremstilling af sildenafil
DK1123284T3 (da) Fremgangsmåde til fremstilling af citalopram
NO980707D0 (no) Fremgangsmåte til fremstilling av kopolymerer
DK0770615T3 (da) Fremgangsmåde til fremstilling af dihalogenazolopyrimidiner
DK1008577T3 (da) Fremgangsmåde til fremstilling af methanol
DK0775100T3 (da) Fremgangsmåde til fremstilling af trifluorethylen
DK0937055T3 (da) Fremgangsmåde til fremstilling af d,I-alfa-tocopherol
DK1027315T3 (da) Fremgangsmåde til fremstilling af n-butanol
DK1028960T3 (da) Fremgangsmåde til fremstilling af thiazolidinedion
DK1053217T3 (da) Fremgangsmåde til fremstilling af n-propanol
DK0996642T3 (da) Fremgangsmåde til fremstilling af heparin
DK0946531T3 (da) Fremgangsmåde til fremstilling af thiazol-derivater
DK0873326T3 (da) Fremgangsmåde til fremstilling af 2-chlorthiazolforbindelser
DK0970939T3 (da) Fremgangsmåde til fremstilling af methanol
DK0864564T3 (da) Særlig fremgangsmåde til fremstillingen af alfa-bromlactamderivater
DK0946514T3 (da) Fremgangsmåde til fremstilling af n-substituerede 3-hydroxypyrazoler
DK2281892T3 (da) Fremgangsmåde til fremstilling af respiratorisk-deficiente Trichoderma-celler
DK0927766T3 (da) Enzymatisk fremgangsmåde til fremstilling af (S)-cyanhydriner